| Primary |
| Carnitine Deficiency |
17.6% |
| Product Used For Unknown Indication |
17.6% |
| Heart Valve Replacement |
11.8% |
| Hepatotoxicity |
11.8% |
| Carnitine Decreased |
5.9% |
| Convulsion |
5.9% |
| Deep Vein Thrombosis |
5.9% |
| Hypersensitivity |
5.9% |
| Liver Disorder |
5.9% |
| Mitochondrial Cytopathy |
5.9% |
| Mitochondrial Myopathy Acquired |
5.9% |
|
| Therapeutic Response Decreased |
22.2% |
| Hypophosphataemia |
11.1% |
| International Normalised Ratio Increased |
11.1% |
| Medication Error |
11.1% |
| Injection Site Swelling |
5.6% |
| Jaundice |
5.6% |
| Poor Quality Sleep |
5.6% |
| Posterior Reversible Encephalopathy Syndrome |
5.6% |
| Product Quality Issue |
5.6% |
| Product Substitution Issue |
5.6% |
| Sinus Tachycardia |
5.6% |
| Status Epilepticus |
5.6% |
|
| Secondary |
| Drug Use For Unknown Indication |
68.9% |
| Product Used For Unknown Indication |
8.1% |
| Hypertension |
5.4% |
| Convulsion |
4.1% |
| Acute Hepatic Failure |
2.7% |
| Non-alcoholic Steatohepatitis |
2.7% |
| Phlebitis |
2.7% |
| Toxicity To Various Agents |
2.7% |
| Complex Partial Seizures |
1.4% |
| Hiv Infection |
1.4% |
|
| Hypophosphataemia |
22.2% |
| Coma |
11.1% |
| Delusion |
11.1% |
| Encephalopathy |
11.1% |
| Leukopenia |
11.1% |
| Mania |
11.1% |
| Posterior Reversible Encephalopathy Syndrome |
11.1% |
| Tinnitus |
11.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.4% |
| Drug Use For Unknown Indication |
26.8% |
| Hiv Infection |
4.8% |
| Hyperparathyroidism Secondary |
3.8% |
| Anaemia |
3.4% |
| Hypertension |
3.3% |
| Epilepsy |
3.1% |
| Diffuse Large B-cell Lymphoma |
3.0% |
| Multiple Myeloma |
2.5% |
| Renal Failure Chronic |
2.2% |
| Sedation |
2.2% |
| Convulsion |
2.1% |
| Medical Diet |
2.1% |
| Peritonitis |
1.9% |
| Bronchial Disorder |
1.3% |
| Analgesic Therapy |
1.2% |
| Colorectal Cancer Metastatic |
1.2% |
| Dialysis |
1.2% |
| Hyperphosphataemia |
1.2% |
| Pain |
1.0% |
|
| Respiratory Tract Infection |
9.5% |
| Weight Increased |
8.6% |
| Urinary Tract Infection |
7.6% |
| Therapeutic Response Decreased |
6.7% |
| Anaemia |
5.7% |
| Neutropenia |
5.7% |
| Drug Ineffective |
4.8% |
| Lethargy |
4.8% |
| Pneumonia |
4.8% |
| Somnolence |
4.8% |
| Ventricular Extrasystoles |
4.8% |
| Weight Decreased |
4.8% |
| Death |
3.8% |
| Fatigue |
3.8% |
| International Normalised Ratio Increased |
3.8% |
| Renal Impairment |
3.8% |
| Septic Shock |
3.8% |
| Anti-erythropoietin Antibody Positive |
2.9% |
| Convulsion |
2.9% |
| Drug Interaction |
2.9% |
|
| Interacting |
| Hiv Infection |
50.0% |
| Blood Cholesterol Increased |
20.0% |
| Deep Vein Thrombosis |
20.0% |
| Herpes Simplex |
10.0% |
|
| Local Swelling |
33.3% |
| Red Blood Cell Count Abnormal |
33.3% |
| Swelling |
33.3% |
|
